---
title: "CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265533599.md"
description: "‒ Q3 2025 Net Revenue of $104.3 million. Pro Forma Net Revenue of $130.8 million ..."
datetime: "2025-11-12T13:04:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265533599.md)
  - [en](https://longbridge.com/en/news/265533599.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265533599.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265533599.md) | [English](https://longbridge.com/en/news/265533599.md)


# CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

‒ Q3 2025 Net Revenue of $104.3 million. Pro Forma Net Revenue of $130.8 million ...

### 相關股票

- [Cormedix (CRMD.US)](https://longbridge.com/zh-HK/quote/CRMD.US.md)

## 相關資訊與研究

- [CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference](https://longbridge.com/zh-HK/news/279132884.md)
- [CorMedix Inc. posts Q4 net revenue of USD 127 million and FY 2025 net revenue of USD 310 million](https://longbridge.com/zh-HK/news/271936840.md)
- [eXoZymes Provides Fourth Quarter and Full Year 2025 Update | EXOZ Stock News](https://longbridge.com/zh-HK/news/281238350.md)
- [Li Auto Inc. March 2026 Delivery Update | LI Stock News](https://longbridge.com/zh-HK/news/281329247.md)
- [VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update | VNRX Stock News](https://longbridge.com/zh-HK/news/281235781.md)